A tablet tool may empower women to prevent HIV — trial puts it to the test
NCT ID NCT04621760
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This trial tests a tablet-based decision support tool designed to help women learn about their HIV risk and prevention options, including PrEP. Women aged 18-45 who are not living with HIV will be randomly assigned to use the tool before a clinic visit or to receive standard counseling. Researchers will survey participants about their knowledge, confidence, and satisfaction, and follow up after three months to see if they started an HIV prevention method. The goal is to see if the tool increases PrEP use and improves decision-making.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A tablet-based decision support tool that educates women about HIV prevention options, including PrEP.
- What this could lead to
- If effective, this tool could help more women at risk of HIV start using PrEP or other prevention methods, potentially reducing HIV rates among women of color.
- What could go wrong
- The trial is small and tests a behavioral tool, not a drug. Results may not apply broadly, and the tool's impact on actual HIV prevention is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
189 people
The number who actually took part.
- Started
-
May 2021
- Finished
-
Nov 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Self-identify as a woman (regardless of pregnancy status) * Age 18 - 45 years * Not known to be living with HIV (based on self-report) * English-speaking * Interested in participating Exclusion Criteria: * Unable to consent * Currently using PrEP * Those who were assigned male at birth and self-identify as a man * Unwilling to be contacted in 3 months * Already participated in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Human immunodeficiency virus transmission are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Florida Department of Health in Duval County
Jacksonville, Florida, 32211, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- HPV infections in transgender people: a hidden health gap gets a closer look
- Peer navigators and mobile clinics aim to slash HIV rates in rural south african youth
- Could a home urine test revolutionize STI screening for men?
- Can a Mother-Daughter workshop cut HIV rates in teen girls?
- Can a quick chat in a family planning clinic curb risky drinking and drug use?
- Could this vaccine stop the superbug gonorrhea?